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Abstract
Innate immune responses play a central role in neuroprotection and neurotoxicity during inflammatory processes that are
triggered by pathogen-associated molecular pattern-exhibiting agents such as bacterial lipopolysaccharide (LPS) and that
are modulated by inflammatory cytokines such as interferon c (IFNc). Recent findings describing the unexpected complexity
of mammalian genomes and transcriptomes have stimulated further identification of novel transcripts involved in specific
physiological and pathological processes, such as the neural innate immune response that alters the expression of many
genes. We developed a system for efficient subtractive cloning that employs both sense and antisense cRNA drivers, and
coupled it with in-house cDNA microarray analysis. This system enabled effective direct cloning of differentially expressed
transcripts, from a small amount (0.5 mg) of total RNA. We applied this system to isolation of genes activated by LPS and
IFNc in primary-cultured cortical cells that were derived from newborn mice, to investigate the mechanisms involved in
neuroprotection and neurotoxicity in maternal/perinatal infections that cause various brain injuries including periventricular
leukomalacia. A number of genes involved in the immune and inflammatory response were identified, showing that
neonatal neuronal/glial cells are highly responsive to LPS and IFNc. Subsequent RNA blot analysis revealed that the
identified genes were activated by LPS and IFNc in a cooperative or distinctive manner, thereby supporting the notion that
these bacterial and cellular inflammatory mediators can affect the brain through direct but complicated pathways. We also
identified several novel clones of apparently non-coding RNAs that potentially harbor various regulatory functions.
Characterization of the presently identified genes will give insights into mechanisms and interventions not only for perinatal
infection-induced brain damage, but also for many other innate immunity-related brain disorders.
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Introduction
Innate immune responses are pivotal in neuroprotection and
neurotoxicity during various inflammatory processes, which are
triggered by agents such as bacterial lipopolysaccharide (LPS) and
modulated by inflammatory cytokines including interferon c
(IFNc) produced mainly by T cells and natural killer cells [1–3].
For example, LPS and IFNc are thought to be involved in brain
disorders [4–6] such as those arising from perinatal intrauterine
infections that cause various brain injuries ranging from periven-
tricular leukomalacia (PVL) with permanent motor impairment
[4,7] to adult-onset neuropsychiatric disorders [8,9]. In the central
nervous system (CNS), pathogen-associated molecular patterns of
infectant products, including LPS, peptidoglycans, and nucleic
acids, are recognized by pattern recognition receptors, i.e. Toll-
like receptor (TLR) family members. Almost all TLR family
members exist on microglia, and some exist on astrocytes,
oligodendrocytes, and neurons [2,10,11]. Some TLRs can also
recognize endogenous cell damage-derived substances, and
subsequently activate the pathways that lead to noninfectious
disorders, such as traumas, ischemia, autoimmune diseases, and
neurodegenerative disorders of the CNS.
Microglia and astrocytes are highly responsive to IFNc, and
microglia also to LPS [10,12,13], leading to the production of the
well-characterized immediate antimicrobial and neurotoxic agent
nitric oxide (NO) by NO synthase (NOS) isoforms such as
inducible NOS (iNOS) and endothelial NOS (eNOS) [14–19]. In
addition to the NO system, comprehensive gene expression
analyses, primarily using microarrays, have identified many other
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candidate genes involved in the LPS and IFNc responses [20–25].
These studies have led to recent characterizations of injury type-
specific markers [26] and inflammatory signaling pathways [27] in
astrocytes, and action mechanisms of immunosuppressive agents
in microglia [28].
The recent characterization of mammalian genomes and
transcriptomes harboring unexpected complexity has prompted
us to further isolate novel transcripts involved in specific
physiological and pathological processes such as neural innate
immunity. Besides microarray analysis [29], the identification of
differentially expressed genes has been accomplished by subtrac-
tive cloning (e.g. [30,31]) differential display [32], serial analysis of
gene expression [33], and next-generation sequencing [34].
Among these procedures, subtractive cloning is the most direct
method to isolate novel cDNA clones, and its refinement can fulfill
current requests to provide specific transcriptome resources. We
recently developed a system that is suitable for both the
construction of cDNA libraries and the quantification of mRNA
levels from only a small amount of mRNA [35,36]. Here, we
applied this system to subtractive cloning. Specifically, efficient
subtraction was accomplished by using the amplified cDNA as a
tester and the mixture of both strands of cRNAs as a driver. The
subtracted cDNA served for preparation and analysis of micro-
arrays, thereby providing a highly efficient system for isolation of
differentially expressed genes. We employed this new system to
identify genes activated by LPS and IFNc in primary-cultured
neuronal/glial cells derived from newborn mice as a means to
study the pathophysiology of PVL, while the genes identified in
this study may be also involved in a broad spectrum of other brain
injuries related to innate immunity.
Materials and Methods
Animals
Pregnant C57BL/6 mice were purchased from Nippon Clea
Co. (Tokyo, Japan), and housed at 2461uC on a 12-h light/12-h
dark cycle with free access to food and water in the Laboratory
Animal Center of Chiba University School of Medicine. All
experimental procedures in this study were approved by the
Animal Experiment Committee of Chiba University (Permit
Numbers: 980005 and 20000008), and were conducted in
accordance with the Guidelines for Proper Conduct of Animal
Experiments of the Science Council of Japan.
Cell Culture
The neonatal mouse neuronal/glial mixed culture was essen-
tially performed as previously described [37]. The cerebral cortices
were removed at postnatal day 1 and placed in the Eagle’s
minimum essential medium (Nissui Pharmaceutical Co., Tokyo,
Japan)/Hank’s balanced salt solution (1:1) mixture containing
10 mM L-glutamine (Invitrogen Corp., Carlsbad, CA), 0.2%
NaHCO3, 10% fetal bovine serum (Invitrogen), 10% horse serum
(Invitrogen), 2% Nu serum (Becton Dickinson Labware, Bedford,
MA), and 12 ng/mL of nerve growth factor (Sigma Chemical Co.,
St. Louis, MO). Cells were mechanically dissociated by trituration
using fire-polished Pasteur pipettes and seeded in 100-mm dishes
coated with 0.2% polyethyleneimine (Sigma). The cultured cells
were maintained in the above mixture without the fetal bovine
serum at 37uC in a humidified incubator with 5% CO2
atmosphere for 1 week. The cells were stimulated by using
10 mg/mL LPS (Escherichia coli serotype O127:B8; Sigma) and 500
units/mL IFNc (recombinant mouse; PBL Biomedical Laborato-
ries, Piscataway, NJ) twice at 6 and 24 h before harvesting for the
subtraction experiments.
cDNA Synthesis and PCR Amplification
Total RNA was prepared from the stimulated (LPS and IFNc)
and non-stimulated primary-cultured neuronal/glial cells using the
acid-guanidine-phenol-chloroform method [38], and was pro-
cessed to amplify the total cDNA using PCR as schematically
illustrated in Fig. 1A. The detailed procedures for Steps 1 and 3–6
were previously described [36]. Briefly, poly(A)+ RNA derived
from 0.5 mg of total RNA was absorbed onto 50 mg of oligo(dT)
magnetic beads Dynabeads Oligo(dT)25 (Dynal, Oslo, Norway),
and was subjected to first-strand and second-strand cDNA
synthesis (Fig. 1A, Step 1). Trimming of the resultant double-
stranded cDNA to an estimated average of 1,024 bp lengths from
the 39-termini (Step 2) was performed by dividing the bead-fixed
cDNA into three aliquots, each of which was digested with one of
three restriction enzymes [BanI, EcoO109I, and HincII (0.5 units)]
in 20 mL of the buffer solution consisting of 20 mM Tris-HCl
(pH 7.9), 10 mM MgCl2, 50 mM KCl, and 1 mM DTT at 37uC
for 1 h. The reaction was stopped by adding 0.8 mL of 0.5 M
EDTA-Na (pH 8.0), and the enzymes were inactivated by heating
the mixture at 65uC for 20 min. The three 39-trimmed cDNA-
bead suspensions were combined, and the beads were washed
three times with 50 mL of 10 mM Tris-HCl (pH 8.0)/1 mM
EDTA (Tris-EDTA buffer, TE). The bead-fixed 39-trimmed
cDNA was blunt-ended with 0.5 units of T4 DNA polymerase
(Roche Diagnostics, Tokyo, Japan) in 20 mL of a mixture
containing 50 mM Tris?HCl (pH 8.8), 15 mM (NH4)2SO4,
7 mM MgCl2, 0.1 mM EDTA, 10 mM 2-mercaptoethanol,
0.02 mg/mL bovine serum albumin, and 0.1 mM each of dATP,
dCTP, dGTP, and dTTP at 16uC for 10 min. The reaction was
stopped by adding 0.8 mL of 0.5 M EDTA-Na (pH 8.0), and the
beads were washed three times with 50 mL of TE. The subsequent
reactions were performed essentially as previously described [36].
The bead-fixed blunt-ended cDNA was ligated with a linker
containing the T7 promoter sequence (Step 3). The sense-strand
cDNA was liberated by heat-denaturation (Step 4), and was again
converted to the double-stranded form using the oligo(dT) primer
containing the SP6 promoter sequence (Step 5). The double-
stranded cDNA was amplified by PCR using known sequences at
both ends as primers (Step 6).
Subtraction Procedures
Driver cRNAs were prepared using the amplified total cDNA
derived from the non-stimulated control cells as a template
(Fig. 1B, Step 7a). The sense and antisense strand cRNAs were
specifically synthesized using T7 and SP6 RNA polymerases,
respectively. The reaction was performed in 20 mL of a mixture
containing 40 mM Tris-HCl (pH 8.0), 6 mM MgCl2, 10 mM
DTT, 2 mM spermidine, 1 mM ATP, 1 mM CTP, 1 mM GTP,
0.9 mM UTP, 0.1 mM biotin-16-UTP (Roche Diagnostics,
Mannheim, Germany), 20 units of human placental RNase
inhibitor (Toyobo, Osaka, Japan), 0.3 mg of the amplified total
cDNA, and 40 units of T7 or SP6 RNA polymerase (Roche
Diagnostics) at 37uC for 2 h. Then, 20 units of DNase I (Roche
Diagnostics) were added to digest the template cDNA, and the
mixture was further incubated for 15 min. The synthesized cRNA
was recovered by ethanol precipitation, washed with 70% ethanol,
and dissolved in 20 mL of H2O.
Tester cDNA (0.5 mg) derived from the LPS/IFNc-stimulated
cells was mixed with 5 mg of the driver biotinylated cRNAs (2.5 mg
each of sense and antisense strands) and dissolved in 30 mL of
H2O. To avoid hybridization at the linker sequences of both ends,
2 mg of the upper strand of the 59-T7 linker and 2 mg of the 39-SP6
oligo(dT) primer were added. The samples were made up to 0.3 M
sodium acetate, precipitated with two volumes of ethanol, washed
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with 70% ethanol, and dissolved in 5 mL of 50 mM Hepes-Na
(pH 8.3), 0.5 M NaCl, 0.02 mM EDTA, and 30% formamide.
After heat denaturation at 98uC for 90 s to dissociate the tester
double-strand cDNA (Step 7b), hybridization was performed at
68uC for 21 h (Step 8).
To remove the biotinylated cRNA-containing mixtures (Step 9),
1 mg of streptavidin-magnetic-beads Dynabeads M-280 Strepta-
vidin (Dynal) in 45 mL of H2O plus 50 mL of the buffer solution
containing 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, and 2 M
NaCl was added to the hybridized mixtures. The binding reaction
of biotin and avidin was performed at room temperature for
10 min. After incubation at 55uC for 3 min to release the non-
specific binding, the streptavidin beads harboring biotinylated
cRNA-containing mixtures were absorbed using magnets, and the
subtracted cDNA in the solution was recovered. After the addition
of 20 mg of glycogen as a carrier, the subtracted cDNA was
ethanol-precipitated, washed with 70% ethanol, and dissolved in
20 mL of TE.
To amplify the subtracted cDNA (Step 10), PCR was performed
in eight tubes each containing 50 mL of a mixture consisting of
20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH4)2SO4,
2 mM Mg SO4, 0.1% Triton X-100, 0.2 mM each of dATP,
dCTP, dGTP, and dTTP, 0.1 mg/mL bovine serum albumin, 1 mL
of the subtracted cDNA solution, 50 pmol each of the 59 and 39
PCR primers, and 1.8 units of PfuTurbo DNA polymerase
(Stratagene, La Jolla, CA). After heat-treatment at 94uC for 3 min,
amplification was performed using 13 cycles of 1 min at 94uC,
2 min at 64uC, and 4 min at 72uC. The eight reactions were
combined and supplemented with 20 mg of glycogen as a carrier.
After extraction with phenol twice, phenol/chloroform twice, and
chloroform twice, the PCR products were recovered by ethanol
precipitation, washed with 70% ethanol, and dissolved in 20 mL of
TE. Typically, 2 mg of PCR products from the subtracted cDNA
were obtained. Using 0.5 mg of the subtracted cDNA as a tester,
subtractive hybridization and PCR amplification were repeated.
Restriction ends for AvaI and AccI were constructed on the 59-
and 39-termini of the amplified cDNA, respectively, by T4 DNA
polymerase in the presence of dATP and dTTP, but not dCTP
and dGTP, thereby allowing the unidirectional insertion of cDNA
into the plasmid vectors [36]. cDNA fragments longer than 600 bp
were gel-purified, and ligated with AvaI/AccI-cut pUC19. The
Escherichia coli strain DH10B (Invitrogen) was then transformed
using the ligation products.
cDNA Microarray Analysis
A microarray chip was prepared as previously described [39]
using cDNA clones derived from the control cells, LPS/IFNc-
stimulated cells, and subtracted products. Sense-strand cRNA
transcribed from the T7 promoter of the bead-fixed cDNA
(Fig. 1A, Step 3 without prior restriction enzyme digestion) was
subjected to aminoallyl incorporation into cDNA during reverse
transcription. The synthesized sense-strand cRNA (0.5 mg) and
2 mg of oligo(dT) in 15.5 mL of solution were heat-denatured at
Figure 1. Schematic illustration of cDNA amplification (A) and subsequent subtraction (B). See the text for explanation.
doi:10.1371/journal.pone.0079236.g001
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70uC for 10 min, and immediately cooled on ice. The solution was
made up to 30 mL of a mixture containing 50 mM Tris-HCl
(pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 0.5 mM
each of dATP, dCTP, and dGTP, 0.2 mM 5-(3-aminoallyl)-dUTP
(Ambion Inc., Austin, TX), and 400 units of reverse transcriptase
SuperScript II (Invitrogen). The reaction was allowed to proceed
at 42uC for 60 min. After alkaline degradation of the template
RNA, the aminoallyl-modified cDNA was purified using MinElute
(Qiagen, Hilden, Germany). Coupling of the aminoallyl-modified
cDNA (0.5 mg) with Cy3 or Cy5 CyDye (Amersham Biosciences,
Tokyo, Japan) was performed according to the manufacturer’s
protocol. The Cy3- and Cy5-labeled cDNAs were mixed, and
made up to 40 mL of a solution containing 1.25 mg/mL yeast RNA,
1.25 mg/mL poly(A), 3.46SSC (16SSC: 0.15 M NaCl/15 mM
sodium citrate), and 0.3% SDS. Hybridization with the microarray
was performed at 65uC overnight under humidified conditions.
After the hybridization, the array was washed twice for 5 min with
26SSC/0.1% SDS at room temperature, twice for 5 min with
0.26SSC/0.1% SDS at 40uC, and finally rinsed with 0.26SSC.
The array was centrifuged at 1,000 rpm for 1 min, and then
scanned using the fluorescence laser-scanning device ScanAr-
ray4000 (GSI Lumonics, Bedford, MA).
Southern and Northern Analysis
Amplified total cDNA mixtures (0.2 mg per lane) were separated
by 1% agarose gel electrophoresis. DNAs were visualized by
ethidium bromide staining, alkaline-denatured, neutralized, and
transferred to nylon membranes. Total RNAs (0.5 mg per lane)
were electrophoresed in denaturing formaldehyde-agarose (1%)
gels. RNAs were visualized by ethidium bromide staining, and
blotted onto nylon membranes. For preparation of antisense
strand-specific probes, plasmids harboring cloned cDNAs were
linearized with an appropriate restriction enzyme, and then
subjected to the synthesis of digoxigenin-labeled cRNA probes
with SP6 polymerase, using a transcription kit (Roche Diagnos-
tics). Hybridization, washing, and chemiluminescent detection on
X-ray films were done as recommended by Roche Diagnostics.
Densitometry was performed using ImageJ 1.46r (National
Institute of Health, Bethesda, MA).
Statistical Analysis
The statistical significance of the enrichment of LPS/IFNc-
induced clones by the subtraction was assessed using a Fisher’s
exact test.
Results
Subtractive Cloning of Genes Activated by LPS and IFNc
To isolate candidate genes involved in brain injuries such as
PVL that is caused by perinatal infections, we used a primary
mixed neuronal/glial culture derived from the cerebral cortex of
postnatal day 1 mice. At this time point, the culture is expected to
resemble the perinatal state of the brain. In addition, the mixed
neuronal/glial culture more closely simulates physiological brain
conditions than cell-type-specific cultures, and thus provides an
excellent starting point for systematic investigations of the neural
responses to LPS and IFNc. The neuronal/glial cells were
stimulated with 10 mg/mL LPS and 500 units/mL IFNc. The
LPS dose was chosen based on our previous studies, in which we
examined NOS mRNA induction in the rat astroglioma C6 cell
line [40] and in the rat brain in vivo [18]. The IFNc dose was
chosen based on other previous reports [41,42], in which its effects
on the growth and apoptosis of rat neural progenitor cells were
examined.
To enrich the genes activated by LPS and IFNc in the
neuronal/glial cultured cells, we employed the subtractive cloning
procedure described in the Materials and Methods and illustrated
in Fig. 1. Since only limited amounts of RNA were obtained from
the primary-cultured cells, we first amplified the total cDNA by
PCR (Fig. 1A). The procedures for Steps 1 and 3–6 [36], and Step
2 in brief [35] have been previously described. Poly(A)+ RNA
derived from 0.5 mg of total RNA of the stimulated (LPS and
IFNc) or non-stimulated cells was absorbed onto oligo(dT)
magnetic beads, and was used as a template for cDNA synthesis
(Fig. 1A, Step 1). To avoid the loss of long cDNA during PCR, we
performed 39-trimming of cDNA by digestion using one of three
restriction enzymes BanI, EcoO109I, and HincII (Step 2) prior to
PCR. The restriction sites for each of these enzymes appear once
in an average of 1,024 bp in random DNA sequences, and the
combination of separate digestion with the three enzymes allows
99.7% of the cDNA population to be trimmed from the 39 termini
into less than 2,000 bp lengths. The restriction ends were blunted
and ligated with a linker harboring the T7 promoter sequence
(Step 3). The sense-strand cDNA liberated by heat denaturation
(Step 4) was subjected to antisense-strand cDNA synthesis-coupled
construction of the SP6 promoter sequence onto the 39 terminus
(Step 5). The total cDNA was amplified by PCR, using the linker
sequences of both ends as primers (Step 6).
In the subtractive hybridization (Fig. 1B), we used a mixture of
both sense and antisense strand cRNAs as a driver, rather than
cDNA. This enabled us to avoid amplification of the contaminat-
ing driver during the PCR amplification of subtracted tester cDNA
after removal of the driver cRNA complexes. As shown in Fig. 1B,
Step 7a, the amplified total cDNA derived from the non-
stimulated control cells were subjected to preparation of
biotinylated-cRNA drivers, by synthesizing sense and antisense
strand cRNAs with T7 and SP6 RNA polymerases, respectively.
The tester cDNA derived from the LPS/IFNc-stimulated cells was
mixed with the driver biotinylated-cRNAs, heat-denatured (Step
7b), and allowed to hybridize (Step 8). The resultant subtracted
cDNA was separated by removing the biotinylated-cRNA-
containing constituents using streptavidin-magnetic-beads (Step
9), and amplified by PCR (Step 10). A portion of the subtracted
cDNA was processed, as a tester, to another round of subtractive
hybridization and PCR amplification (repetition from Step 7b to
Step 10).
As shown in Fig. 2, the original total cDNA and subtracted
cDNAs were subjected to Southern analysis to determine the
subtraction efficiency. Serial two-round subtractions allowed
enrichment of cDNA of interferon gamma inducible protein 47
(IFI47) [43,44] as a positive control. Comparatively, the glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) cDNA almost
completely vanished after the second-round subtraction. There-
fore, the present procedure facilitated effective subtraction.
Our system enabled the construction of unique restriction ends
on 59 and 39 termini of amplified cDNA fragments [36], and then
their unidirectional insertion into plasmids. We prepared a library
of the subtracted cDNA, as well as of control cell-derived and
LPS/IFNc-stimulated cell-derived cDNA, and determined the 59-
end sequences of randomly-selected cDNA clones. We then
constructed an in-house microarray containing 124 subtracted
cDNA clones, as well as 97 control cell-derived and 105 LPS/
IFNc-stimulated cell-derived cDNA clones. The array was
hybridized with a target mixture of Cy3-labeled cDNA derived
from LPS/IFNc-stimulated cells and Cy5-labeled cDNA derived
from non-stimulated control cells. Hybridization was also
performed with a target mixture of cDNAs interchanged for
Cy3/Cy5 labeling to correct possible biases such as intensity-
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dependent fluorescence differences between the two dyes. The
results of the two hybridizations were averaged, and the
distribution of fold-changes in the mRNA levels in response to
LPS/IFNc stimulation was determined for the three groups of
array spots: control cell-derived, LPS/IFNc-stimulated cell-
derived, and subtracted cDNAs (Fig. 3). Importantly, the
subtracted cDNA population was enriched with LPS/IFNc-
activated genes. Indeed, 58% of the subtracted clones had at least
1.5-fold change. This distribution is significantly (P,0.001,
Fisher’s exact test) higher than that of the clones derived from
the LPS/IFNc-stimulated cells, thereby confirming the successful
enrichment of the LPS/IFNc-induced clones by subtraction.
Predominant Categories of Genes Activated by LPS and
IFNc
The LPS/IFNc-activated genes with at least 1.5-fold change in
the array analysis are listed in Table 1 after eliminating the
redundancies. Strikingly, genes belonging to three categories were
predominant. The first category includes chemokine genes:
chemokine (C-C motif) ligand 2 (Ccl2; No. 8), Ccl5 (No. 1), Ccl7
(No. 5), Ccl19 (No. 45), chemokine (C-X-C motif) ligand 1 (Cxcl1;
No. 31), Cxcl9 (No. 4), Cxcl10 (No. 11), and Cxcl11 (No. 14). The
second contains genes for GTPases involved in protection against
intracellular pathogens [44–46]: guanylate binding protein 2
(Gbp2; No. 10), Gbp3 (No. 40), Gbp4 (No. 20), Gbp6 (No. 7), Ifi47
(No. 16), immunity-related GTPase family M member 2 (Irgm2;
No. 23), and T-cell specific GTPase 2 (Tgtp2; No. 3). The third
category pertains to genes involved in antigen presentation:
histocompatibility 2 (H2), class II antigen A, b1 (H2-Ab1;
No. 26), H2-DMa (No. 25), H2-K1 (No. 22), H2-Q10 (No. 58),
b2 microglobulin (B2m; No. 37), proteasome subunit b8 (Psmb8;
No. 27), Psmb9 (No. 18), Psmb10 (No. 32), transporter associated
with antigen processing 1 (Tap1; No. 21); and possibly proteasome
assembly chaperone 4 (Psmg4; No. 52), ubiquitin D (Ubd; No. 13),
and ubiquitin-conjugating enzyme E2M (Ube2m; No. 60).
Differential Gene Activation by LPS and IFNc
For several selected genes, the time-dependent changes in the
mRNA levels in response to LPS and/or IFNc were examined by
Northern analysis (Fig. 4). In the present experimental system,
cDNA clones of the subtracted libraries were ready to serve as
templates for antisense strand-specific cRNA probes, as described
in the Materials and Methods. Coadministration of LPS and IFNc
was required for strong induction of the mRNAs of the
chemokines CCL5 (No. 1), CXCL9 (No. 4), and CCL2 (No. 8).
The mRNA levels of serum amyloid A3 (SAA3; No. 2) and
lipocalin 2 (No. 6) were mainly responsive to LPS, while those for
the GTPases GBP-2 (No. 10) and IFI47 (No. 16) were mainly
responsive to IFNc. Therefore, these genes displayed differential
patterns with respect to their responsiveness to LPS and IFNc.
The gene activation profiles in Fig. 4 are concordant with the
notion that both LPS and IFNc can affect the brain cells through
direct but complicated means. It remains to be investigated what
cell type is responsible for each gene activation in the present
mixed neuronal/glial culture system.
Putative Non-Coding RNAs Induced by LPS and IFNc
Table 1 includes novel transcripts: clone No. 42 derived from
subtracted products, and clone Nos. 61 and 74 derived from
control cells. These are apparently non-coding RNAs because
even the longest open reading frame harboring the initiation ATG
codon corresponded to only 35 amino acids (No. 61,
chr19:25,002,938–25,003,042) in these clones. In Fig. 5, their
chromosome loci are represented alongside the screen shots from
the University of California Santa Cruz (UCSC) Genome
Browser.
Clone No. 42 (Fig. 5A) contained the 279-bp segment
corresponding to chr5:92,787,601–92,787,879 (minus strand)
situated between the Cxcl10 and Cxcl11 loci, which in turn are
located in a large (,55 kb) intron of Art3. As previously noted [20–
23,47,48], Cxcl10 and Cxcl11 are activated by LPS and IFNc
(Table 1, Nos. 11 and 14). According to the RNA-Seq data of the
UCSC Browser (Fig. 5A), expression levels of Cxcl10 and Cxcl11
Figure 2. Monitoring subtraction processes. PCR-amplified cDNA
mixtures (0.2 mg) derived from the control cells (C), cells stimulated by
LPS and IFNc (L/I), first-round subtracted products (S1), and second-
round subtracted products (S2) were electrophoresed, stained (top
panel), and subjected to Southern analysis to detect the cDNAs of
interferon gamma inducible protein 47 (IFI47) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
doi:10.1371/journal.pone.0079236.g002
Figure 3. Subtraction efficiency evaluated by cDNA microarray
analysis. An in-house microarray containing cDNA clones derived from
the control cells (gray bars, 97 spots in total), LPS/IFNc-stimulated cells
(white bars, 105 spots), and subtracted products (black bars, 124 spots)
was prepared, and analyzed for changes in the mRNA levels in response
to LPS and IFNc. The percentages of the clones that had altered mRNA
levels indicated in the horizontal axis are plotted for each clone group.
doi:10.1371/journal.pone.0079236.g003
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are low in the normal cerebrum, while higher expression levels are
seen in the normal liver that may have been exposed to
enteromicrobial products. The locus of clone No. 42 overlaps or
adjoins the genome sequences exhibiting the features characteristic
of enhancers: sequence conservation in the intergenic regions [49],
DNaseI hypersensitivity [50,51], and binding to histone H3
monomethylated at lysine 4 (H3K4me1) [52] and H3 acetylated at
lysine 27 (H3K27ac) [53,54]. These features are more prominent
in the liver than in the brain, which correlates with the expression
levels of Cxcl10 and Cxcl11. It is plausible that clone No. 42
corresponds to a transcript started from an enhancer [55], i.e.
enhancer RNA (eRNA) [56].
Clone No. 61 (Fig. 5B) contained the 598-bp segment
corresponding to chr19:25,002,842–25,003,439 (plus strand)
complementary to the sequence spanning the intron 10–exon 11
junction of the COBW domain containing 1 (Cbwd1) gene. This
location is reminiscent of roles of antisense RNAs complementary
to exon-intron boundaries of mRNA precursors in the regulation
of alternative splicing, as has been demonstrated for a number of
genes [57–59].
Clone No. 74 (Fig. 5C) contained the 541-bp segment
corresponding to chr17:17,516,696–17,517,236 (minus strand)
complementary to transcripts of the RIO kinase 2 (Riok2) gene.
Riok2 has two major transcription start sites, and the clone No. 74
sequence is complementary to intron 3 or exon 1 of each
alternative transcript. It is tempting to speculate that this antisense
RNA differentially regulates alternative Riok2 transcripts in mRNA
precursor processing and/or mRNA activity.
Discussion
Identification of genes with altered expression levels in
physiological and pathological processes is a promising strategy
to obtain insights into underlying genetic mechanisms. We have
developed a system of subtractive cloning coupled with in-house
cDNA microarray analysis for the efficient isolation of differen-
tially expressed genes. It enabled the identification of transcripts
induced by LPS and IFNc in primary-cultured mixed neuronal/
glial cells derived from neonatal mice. Newly identified genes
included those for novel putative non-coding RNAs potentially
possessing various regulatory functions, suggesting the feasibility of
the present system for direct isolation of the transcripts that
represent emerging complexity of mammalian genomes and
transcriptomes.
As for protein-coding genes, the list (Table 1) included a number
of genes for chemokines, GTPases, and antigen presentation
pathways. In previous studies using cultures enriched in microglia
[22,24] and astrocytes [20,21,25–27] as well as immortalized
microglial cell lines [23,28], these genes have been described as
typical examples of genes activated by LPS and IFNc, which
supports the validity of our system to identify differentially
expressed genes. Interestingly, a growing number of functions
have been assigned to these genes, not only in immunity and
inflammation but also in many physiological processes. Chemo-
kines were originally identified as chemotactic cytokines involved
in leukocyte migration associated with inflammation [60].
Recently, chemokine receptors have also been found in neurons
and glial cells of the CNS [61], and the chemokine system is
implicated in CNS functions such as neuromodulatory/neuro-
transmitter activities [62,63]. GTPases are best known for their
roles in protection against intracellular pathogens [44–46]. In
addition, GTPases have been assigned functions in processes such
as cell proliferation, specification, and death [46]. While genes for
antigen presentation pathways are central players in adaptive
immunity, their members, such as the major histocompatibility
complex class I H2-Kb and H2-Db genes, have been recently
identified for their roles in the regulation of developmental ocular
dominance [64] and adult motor learning [65] as well as neuronal
death and motor recovery after ischemia [66]. Therefore, it will be
interesting to investigate the roles of the genes encoding
chemokines, GTPases, and members of antigen presentation
pathways in Table 1 not only as mediators of inflammatory
responses but also as regulators of neural development and
plasticity in normal and disease-associated processes.
An example of innate immunity-related disorders resulting in
severe brain damage is PVL, which is a predominant form of
cerebral palsy with white matter injury in preterm infants [67].
PVL is characterized by small multifocal zones of necrosis, in
Figure 4. Time course of changes in mRNA levels of several
genes in response to LPS and IFNc. Total RNAs were prepared from
primary-cultured neuronal/glial cells stimulated by IFNc (I), LPS (L), or
both (I/L) for indicated periods. RNAs (0.5 mg per lane) were
electrophoresed and subjected to Northern analysis for the indicated
mRNAs and for GAPDH mRNA as a control. Below the chemilumino-
gram, the densitometrically quantified band intensities are shown. ‘‘2’’
indicates that the band intensity was below the detectable level.
doi:10.1371/journal.pone.0079236.g004
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Table 1. Genes activated by LPS and IFNc.
No.
Fold
induction
Subtrac-
tiona Accession Gene name
1 80.12 S NM_013653.3 Ccl5 chemokine (C-C motif) ligand 5
2 64.10 S NM_011315.3 Saa3 serum amyloid A 3
3 57.13 NM_001145164.1 Tgtp2 T-cell specific GTPase 2
4 51.70 S NM_008599.4 Cxcl9 chemokine (C-X-C motif) ligand 9
5 50.91 S NM_013654.3 Ccl7 chemokine (C-C motif) ligand 7
6 49.94 S NM_008491.1 Lcn2 lipocalin 2
7 49.87 S NM_194336.2 Gbp6 guanylate binding protein 6
8 44.82 S NM_011333.3 Ccl2 chemokine (C-C motif) ligand 2
9 33.02 S NM_011018.2 Sqstm1 sequestosome 1
10 31.61 S NM_010260.1 Gbp2 guanylate binding protein 2
11 30.66 S NM_021274.1 Cxcl10 chemokine (C-X-C motif) ligand 10
12 30.24 S NM_010738.2 Ly6a lymphocyte antigen 6 complex, locus A
13 28.95 S NM_023137.3 Ubd ubiquitin D
14 26.36 S NM_019494.1 Cxcl11 chemokine (C-X-C motif) ligand 11
15 26.11 S NM_009778.2 C3 complement component 3
16 24.00 S NM_008330.1 Ifi47 interferon gamma inducible protein 47
17 22.21 S NM_009396.2 Tnfaip2 tumor necrosis factor, alpha-induced protein 2
18 18.23 S NM_013585.2 Psmb9 proteasome (prosome, macropain) subunit, beta type 9 (large
multifunctional peptidase 2)
19 17.66 S NM_144938.2 C1s complement component 1, s subcomponent
20 17.13 S NM_008620.3 Gbp4 guanylate binding protein 4
21 13.67 S NM_013683.2 Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
22 13.14 S NM_001001892.2 H2-K1 histocompatibility 2, K1, K region
23 11.81 NM_019440.3 Irgm2 immunity-related GTPase family M member 2
24 10.36 S NM_139198.2 Plac8 placenta-specific 8
25 10.31 S NM_010386.3 H2-DMa histocompatibility 2, class II, locus DMa
26 10.23 S NM_207105.3 H2-Ab1 histocompatibility 2, class II antigen A, beta 1
27 8.50 S NM_010724.2 Psmb8 proteasome (prosome, macropain) subunit, beta type 8 (large
multifunctional peptidase 7)
28 7.79 S NM_008198.2 Cfb complement factor B
29 7.76 S NM_013671.3 Sod2 superoxide dismutase 2, mitochondrial
30 7.69 NM_008987.3 Ptx3 pentraxin related gene
31 6.67 S NM_008176.3 Cxcl1 chemokine (C-X-C motif) ligand 1
32 6.51 S NM_013640.3 Psmb10 proteasome (prosome, macropain) subunit, beta type 10
33 6.48 S NM_007575.2 Ciita class II transactivator
34 6.44 NM_010493.2 Icam1 intercellular adhesion molecule 1
35 5.80 S NM_010501.2 Ifit3 interferon-induced protein with tetratricopeptide repeats 3
36 5.78 S NM_133662.2 Ier3 immediate early response 3
37 5.72 NM_009735.3 B2m beta-2 microglobulin
38 5.40 NM_010579.2 Eif6 eukaryotic translation initiation factor 6
39 5.34 NM_011693.3 Vcam1 vascular cell adhesion molecule 1
40 4.76 NM_018734.3 Gbp3 guanylate binding protein 3
41 4.40 NM_007752.2 Cp ceruloplasmin
42 4.10 S AB811352 LIs01G08 chr5:92,787,601-92,787,879 (minus strand)
43 3.94 S NM_025992.2 Herc6 hect domain and RLD 6
44 3.49 S NM_019946.4 Mgst1 microsomal glutathione S-transferase 1
45 3.35 S NM_011888.2 Ccl19 chemokine (C-C motif) ligand 19
46 3.22 S NM_026055.1 Rpl39 ribosomal protein L39
47 2.98 NM_008300.3 Hspa4 heat shock protein 4
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particular around the regions adjacent to the external angles of the
lateral ventricles. While hypoxia-ischemia is a likely convergent
point leading to PVL, recent clinical and experimental data
support a strong correlation between maternal-fetal infection and
PVL [4–6]. In addition, stimulation of microglial TLR4 by LPS
leads to neurodegeneration resembling PVL [68,69], suggesting
the direct causative role of LPS in PVL-associated brain injury. It
was proposed that LPS, as well as IFNc produced during the
course of infection, activates microglia and astrocytes, thereby
resulting in damaged oligodendrocytes in PVL [4–6]. The present
Table 1. Cont.
No.
Fold
induction
Subtrac-
tiona Accession Gene name
48 2.86 S NM_009851.2 Cd44 CD44 antigen
49 2.85 NM_011879.2 Ik IK cytokine
50 2.78 NM_001163590.1 Stx11 syntaxin 11
51 2.66 S NM_008871.2 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1
52 2.62 S NM_001101430.1 Psmg4 proteasome (prosome, macropain) assembly chaperone 4
53 2.57 S NM_010681.4 Lama4 laminin, alpha 4
54 2.52 S NM_145934.1 Stap2 signal transducing adaptor family member 2
55 2.51 NM_133701.2 Prpf6 PRP6 pre-mRNA splicing factor 6 homolog (yeast)
56 2.41 S NM_175389.4 Rg9mtd2 RNA (guanine-9-) methyltransferase domain containing 2
57 2.39 S NM_001113529.1 Csf1 colony stimulating factor 1 (macrophage)
58 2.37 S NM_010391.4 H2-Q10 histocompatibility 2, Q region locus 10
59 2.35 S NM_021524.2 Nampt nicotinamide phosphoribosyltransferase
60 2.33 NM_145578.2 Ube2m ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast)
61 2.28 AB811353 Co101C12 chr19:25,002,842-25,003,439 (plus strand)
62 2.24 NM_021511.2 Rrs1 RRS1 ribosome biogenesis regulator homolog (S. cerevisiae)
63 2.23 S NM_001083938.2 Rnaset2a ribonuclease T2A
64 2.22 NM_178252.2 Arhgap33 Rho GTPase activating protein 33
65 2.19 S NM_001008232.2 Asap3 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3
66 2.14 S NM_018825.3 Sh2b2 SH2B adaptor protein
67 2.14 S NM_009780.2 C4b complement component 4B (Childo blood group)
68 2.13 NM_001081270.1 Dscaml1 Down syndrome cell adhesion molecule-like 1
69 2.04 S NM_001205081.1 Trim47 tripartite motif-containing 47
70 1.99 BB142106.1 BB142106 RIKEN full-length enriched, adult female vagina Mus musculus cDNA clone
9930013N19 3-, mRNA sequence
71 1.97 S NM_011590.2 Timm17a translocase of inner mitochondrial membrane 17a
72 1.95 NM_011937.2 Gnpda1 glucosamine-6-phosphate deaminase 1
73 1.95 NM_028040.2 Rpusd4 RNA pseudouridylate synthase domain containing 4
74 1.95 AB811354 Co301F01 chr17:17,516,696-17,517,236 (minus strand)
75 1.93 S NM_010239.1 Fth1 ferritin heavy chain 1
76 1.91 NM_024177.3 Mrpl38 mitochondrial ribosomal protein L38
77 1.89 NM_001165991.1 Arfrp1 ADP-ribosylation factor related protein 1
78 1.82 S BI990686.1 4074-27 Mouse E14.5 retina lambda ZAP II Library Mus musculus cDNA, mRNA sequence
79 1.81 NM_144804.1 Depdc7 DEP domain containing 7
80 1.78 NM_023142.2 Arpc1b actin related protein 2/3 complex, subunit 1B
81 1.76 NM_001025102.1 2700007P21Rik RIKEN cDNA 2700007P21 gene
82 1.70 S NM_029166.2 Uhrf1bp1l UHRF1 (ICBP90) binding protein 1-like
83 1.70 S NM_009294.3 Stx4a syntaxin 4A (placental)
84 1.63 NM_007459.3 Ap2a2 adaptor protein complex AP-2, alpha 2 subunit
85 1.60 S NM_011034.4 Prdx1 peroxiredoxin 1
86 1.56 NM_177707.3 Stac3 SH3 and cysteine rich domain 3
87 1.54 NM_199304.1 Zfp341 zinc finger protein 341
aGenes obtained by subtractive cloning are marked ‘‘S’’.
doi:10.1371/journal.pone.0079236.t001
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study showed that neonatal neuronal/glial cells are highly
responsive to LPS and IFNc and that a large number of genes
are activated by these agents. These findings, in addition to the
immaturity of the infant blood-brain barrier [70,71], suggest that
LPS and IFNc during extra-cerebral infections such as intrauter-
ine infection can cause perinatal brain injury in a direct but
complicated manner. The mRNA induction profiles in Fig. 4, in
which LPS and IFNc differentially activate target genes, are also
concordant with this notion.
Many of the regulatory mechanisms underlying the cooperative
or distinctive gene activation by LPS and IFNc observed in Fig. 4
remain to be investigated. In this study, we used a mixed
neuronal/glial culture system, which more closely simulates
physiological brain conditions than cell-type-specific cultures.
However, use of this system necessitates determining what cell
type is responsible for each gene activation. According to previous
reports, the LPS receptor TLR4 is expressed on microglia, and is
expressed at lower levels, if at all, on astrocytes, oligodendrocytes,
and neurons [2; and references therein]. In contrast, the IFNc
receptor is expressed on all of these cell types [72; and references
therein]. Previous comprehensive analyses of LPS- and IFNc-
responsive genes in neural cells [20–25,27,28] were mainly
performed using either primary cultures enriched in microglia or
astrocytes or established cell lines. Comparison of our results with
the results from these previous studies revealed interesting
differences. For example, in Fig. 4, strong induction of CCL2,
CCL5, and CXCL9 mRNAs required coadministration of LPS
and IFNc, whereas previous studies reported that these mRNAs
were induced by administration of LPS alone in primary-cultured
microglia [22], astrocytes [25], and microglial BV-2 cells [28], as
well as by administration of IFNc alone in primary-cultured
astrocytes [21]. In the present study, strong induction of GBP-
2 mRNA mainly depended on IFNc stimulation (Fig. 4), but, in
the previous study [22], it was caused by administration of LPS on
primary-cultured microglia. Astrocytes derived from postnatal day
30–35 mice that were administered an intraperitoneal injection of
LPS also exhibited strong induction of GBP-2 mRNA [26].
Precise comparative examination of the experimental conditions
that caused these differences in the LPS and IFNc responses may
lead to insights into the intercellular regulatory networks among
different neuronal/glial cell types.
Besides PVL, TLR4 stimulation is implicated in a number of
brain injuries, as well as pathogen elimination [10,12,73]. In
addition to presumably microbial product-associated diseases such
as experimental autoimmune encephalomyelitis, a murine model
of multiple sclerosis [74], the involvement of TLR4 has also been
reported in apparently noninfectious disorders such as neuropathic
pain caused by transection of the spinal nerves [75] and ischemic
brain injury [76,77]. In Alzheimer’s disease, TLR4 may exhibit
beneficial or deleterious effects, depending on the conditions of its
activation [11]. Recently, the involvement of TLR4 in alcoholism
has been reported [78,79]. Insights into the underlying mecha-
nisms and possible interventions for these TLR4-mediated brain
disorders would be also provided by clarifying the roles of the
presently identified genes, including those for non-coding RNAs,
activated by the natural TLR4 ligand LPS and/or its effective
modulator IFNc.
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